Adcetris 50 MG vial 1S
Ended Awarded Last action
- Contract number
- SPE2DR26FBTGW
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $24,860
Award facts
- Contract value 100% obligated
- $24,860.28 Current and potential, with all options
- Completion date
- Current and potential, with all options
- NAICS code
- 325411 Medicinal and Botanical Manufacturing
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $24,860.28 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Adcetris (brentuximab vedotin) 50 mg vials. This delivery order, issued on December 17, 2025, represents a single transaction under DMS Pharmaceutical Group's broader Indefinite Delivery Contract with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative. No set-aside designation was applied to this award, indicating the contractor competed in an unrestricted procurement environment. Adcetris is a targeted cancer therapy used primarily in the treatment of Hodgkin lymphoma and certain types of non-Hodgkin lymphoma, reflecting the critical role DMS Pharmaceutical Group plays in supplying specialized pharmaceutical products to Department of Defense military healthcare facilities.
DMS Pharmaceutical Group holds a single-award IDC under the PPV-G GEN V program with a $499.999 billion ceiling and a completion date of December 31, 2036, positioning the company as a regional prime vendor within the DLA's broader $30.3 billion pharmaceutical supply strategy. The PPV-G GEN V contract, awarded on November 13, 2025, authorizes the DLA to issue delivery orders for a comprehensive range of pharmaceutical products, biologics, and medical consumables to support military medical facilities worldwide. This delivery order for Adcetris exemplifies the type of specialized oncology medication that DMS Pharmaceutical Group regularly distributes through its federal supply chain operations, demonstrating the company's capability to fulfill diverse and specialized pharmaceutical requirements across the Department of Defense healthcare system.
Quick answers
Who was awarded contract SPE2DR26FBTGW?
SPE2DR26FBTGW was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 17, 2025.
How much is contract SPE2DR26FBTGW worth?
The government has obligated $24,860 on SPE2DR26FBTGW.
Is contract SPE2DR26FBTGW an order under another contract?
Yes. SPE2DR26FBTGW is a delivery order under SPE2DR25D9628, an indefinite delivery contract.
Was contract SPE2DR26FBTGW competed?
The extent of competition for SPE2DR26FBTGW was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award